DepoMed News

MENLO PARK, Calif., May 25, 2012 /PRNewswire/ -- Depomed, Inc. today announced that it will be presenting at the Jefferies Global Health Care Conference in New York City.

MENLO PARK, Calif., May 10, 2012 /PRNewswire/ -- Depomed, Inc. today announced that it will be presenting at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada.

FDA approved Merck's JanumetA XR extended-release) tablets; initial royalty to Depomed recognized in first quarter 2012 "Our first quarter results highlight the advances we have made toward transforming Depomed into a successful specialty pharmaceutical company," said , president and chief executive officer of Depomed.

Shares of Depomed traded down 0.53% during mid-day trading on Wednesday, hitting $5.68. Depomed has a 52 week low of $4.20 and a 52 week high of $9.26. The company has a market cap of $315.6 million and a P/E ratio of 4.53. Depomed last announced its earnings results on Tuesday, May 8th.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Depomed, Inc.